Systemic administration of the antisense oligonucleotide NS‐089/NCNP‐02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I/II clinical trial

AIM: The purpose of this study is to evaluate the safety and pharmacokinetics of the novel morpholino oligomer NS‐089/NCNP‐02 which can induce exon 44 skipping, in patients with DMD. Additionally, we aimed to identify markers predictive of therapeutic efficacy and determine the optimal dosing for fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishizuka, Takami, Komaki, Hirofumi, Asahina, Yasuko, Nakamura, Harumasa, Motohashi, Norio, Takeshita, Eri, Shimizu‐Motohashi, Yuko, Ishiyama, Akihiko, Yonee, Chihiro, Maruyama, Shinsuke, Hida, Eisuke, Aoki, Yoshitsugu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275280/
https://www.ncbi.nlm.nih.gov/pubmed/37326950
http://dx.doi.org/10.1002/npr2.12335

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275280/
https://www.ncbi.nlm.nih.gov/pubmed/37326950
http://dx.doi.org/10.1002/npr2.12335

Ejemplares similares